DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists.

Our goals are:

- to harmonize the protocols involved in patient documentation, biomaterial sampling/storage, biomarker testing/assay analysis and data sharing
- to standardize a more precise diagnosis in patients with rapidly progressive dementia by analysis of the biochemical markers in the cerebrospinal fluid and blood.
- to improve CSF based diagnosis in dementia by application of new methodologies

We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define standards for biochemically based diagnosis in most relevant rapid progressive dementia such as CJD and rapidly progressive Alzheimer’s disease. We will improve innovative methods for amplification assays for mis-folded proteins and introduce their use into clinical routine. As an add-on value, we will define criteria for early differential diagnosis between rapidly progressive neurodegenerative or potentially reversible dementia.

Total Funding: € 2.2 million (approx.)
Start Date: May, 2012
Duration: 3 years
Coordinator: Inga Zerr
T: +49-551-396636
E: ingazerr@med.uni-goettingen.de

Project Partners:

Inga Zerr, University Medical Center Göttingen, National Reference Center for TSE, Germany
Carsten Korth, Heinrich Heine University Medical School, Düsseldorf, Germany
Hans Kretzschmar, Ludwig-Maximilians-University, Munich, Germany
Jean-Louis Laplanche, Hopital Lariboisiere AP-HP, France
Olivier Andreoletti, UMR-INRA-EVNT, France
Theodoros Sklaviadis, Aristotle University of Thessaloniki, Greece
Stefano Ruggieri & Maurizio Pocchiarli & Anna Ladogana, University “Sapienza”, Rome, Italy
Paweł Liberski, Medical University of Lodz, Poland
Catarina Resende Oliveira, University of Coimbra, Portugal
Eva Milrova, Slovak Medical University Bratislava, Slovakia
Gorazd Bernard Stokin, University Psychiatric Hospital, Ljubljana, Slovenia
Miguel Calero, Carlos III National Health Institute, Spain
Pascual Sanchez-Juan, IFIMAV and CIBERNED, University Hospital, Spain
Anna-Lena Hammarin, Swedish Institute of Communicable Disease Control, Sweden
Adriano Aguzzi & Herbert Budka, University Hospital Zürich, Switzerland
John Collinge, University College London, United Kingdom
Robert G. Will, Western General Hospital, United Kingdom